{
  "id": "5c73ad097c78d69471000092",
  "type": "summary",
  "question": "What is the mechanism of action of Solriamfetol?",
  "ideal_answer": "Solriamfetol is a selective norepinephrine-dopamine reuptake inhibitor. It is used to treat excessive sleepiness in obstructive sleep apnea and narcolepsy patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30365900",
    "http://www.ncbi.nlm.nih.gov/pubmed/30269642",
    "http://www.ncbi.nlm.nih.gov/pubmed/30521757",
    "http://www.ncbi.nlm.nih.gov/pubmed/29891587"
  ],
  "snippets": [
    {
      "text": "Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29891587",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The dual activity of solriamfetol at DA and NE transporters and the lack of significant monoamine-releasing properties of solriamfetol might explain the differences in the in vivo effects of solriamfetol compared with modafinil or amphetamine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29891587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND:: This study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269642",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class that is being considered by the US Food and Drug Administration (FDA) to treat excessive sleepiness in OSA and narcolepsy patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30365900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: To evaluate the efficacy and safety of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30521757",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, the wake-promoting effects of solriamfetol are probably owing to activity at DA and NE transporters rather than other neurotransmitter systems, such as histamine or orexin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29891587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results indicate that solriamfetol has dual reuptake inhibition activity at dopamine (DA; IC50 = 2.9 \u03bcM) and norepinephrine (NE; IC50 = 4.4 \u03bcM) transporters, and this activity is associated in vivo with increased extracellular concentration of DA and NE as measured by microdialysis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29891587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class that is being considered by the US Food and Drug Administration (FDA) to treat excessive sleepiness in OSA and narcolepsy patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30365900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND:\nThis study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269642",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A new drug, solriamfetol, a selective norepinephrine-dopamine reuptake inhibitor, is the first drug of its class that is being considered by the US Food and Drug Administration (FDA) to treat excessive sleepiness in OSA and narcolepsy patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30365900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.Solriamfetol appears to have abuse potential similar to or lower than phentermine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30269642",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Results indicate that solriamfetol has dual reuptake inhibition activity at dopamine (DA; IC<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29891587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, the wake-promoting effects of solriamfetol are probably owing to activity at DA and NE transporters rather than other neurotransmitter systems, such as histamine or orexin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29891587",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To evaluate the efficacy and safety of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor with robust wake-promoting effects, for the treatment of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apnea treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30521757",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}